OverviewSuggest Edit

Albireo is an independent biotechnology company, which brings unique translational approaches to develop drugs that fulfil unmet medical needs in the gastrointestinal (GI) area. The team has a broad experience in drug development, primarily in the GI area and has an extensive network in the international scientific and clinical communities.
TypePublic
Founded2003
HQBoston, MA, US
Websitealbireopharma.com

Latest Updates

Employees (est.) (Feb 2020)55(+42%)
Job Openings7
Revenue (FY, 2020)$8.3 M(-13%)
Share Price (Sept 2021)$28.9(-2%)
Cybersecurity ratingAMore

Key People/Management at Albireo Pharma

Jason Duncan

Jason Duncan

Chief Legal Officer and General Counsel
Michael Gutch

Michael Gutch

Director
Pamela Stephenson

Pamela Stephenson

Chief Commercial Officer
Roger A. Jeffs

Roger A. Jeffs

Director
Michelle Graham

Michelle Graham

Chief Human Resources Officer
Ron Cooper

Ron Cooper

Director, President and Chief Executive Officer
Show more

Albireo Pharma Office Locations

Albireo Pharma has offices in Boston and Göteborg
Boston, MA, US (HQ)
10 Post Office Square #502
Göteborg, SE
Arvid Wallgrens backe 20
Show all (2)

Albireo Pharma Financials and Metrics

Albireo Pharma Revenue

Albireo Pharma's revenue was reported to be $8.31 m in FY, 2020
USD

Revenue (FY, 2020)

8.3m

Net income (FY, 2020)

(107.6m)

EBIT (FY, 2020)

(96.3m)

Market capitalization (14-Sept-2021)

554.3m

Closing stock price (14-Sept-2021)

28.9

Cash (31-Dec-2020)

251.3m

EV

312.7m
Albireo Pharma's current market capitalization is $554.3 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

12.7m9.6m8.3m

General and administrative expense

9.3m6.8m6.8m5.6m6.4m10.3m15.2m18.1m23.0m42.4m

R&D expense

13.9m12.6m14.3m14.2m13.4m3.7m13.0m31.7m45.6m76.8m

Operating expense total

23.2m19.4m21.1m19.8m19.8m14.0m28.2m49.8m68.5m119.2m
Quarterly
USDQ3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

1.0k1.0k11.2m730.0k237.0k570.0k1.3m1.4m1.5m1.9m2.1m

General and administrative expense

2.4m2.0m1.8m1.8m1.4m2.1m1.7m1.4m1.7m1.3m1.8m1.6m1.5m1.6m4.0m3.0m3.2m3.7m3.7m4.1m4.2m3.9m5.3m5.5m6.0m8.2m8.5m11.7m

R&D expense

2.9m2.4m2.6m3.0m4.7m3.0m3.6m3.7m4.3m3.6m3.4m2.9m5.1m1.6m2.1m64.0k2.8m3.0m3.2m6.2m6.4m9.7m8.3m11.0m12.0m16.1m18.4m22.2m

Operating expense total

5.3m4.4m4.5m4.7m6.1m5.1m5.2m5.1m6.0m5.0m5.2m4.5m6.6m3.2m6.1m3.1m6.0m6.7m6.9m10.3m10.6m13.5m13.6m16.5m18.0m24.3m26.9m33.9m
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

38.7m39.1m39.8m24.6m40.8m29.9m53.2m163.9m131.8m251.3m

Accounts Receivable

1.0k9.0k344.0k726.0k2.9m

Prepaid Expenses

399.0k295.0k264.0k311.0k262.0k1.1m850.0k10.0m10.6m

Current Assets

39.2m39.5m40.1m24.9m41.1m30.9m55.0m167.7m141.8m261.9m
USDQ3, 2011

Financial Leverage

1.4 x
Show all financial metrics

Albireo Pharma Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

Albireo Pharma Online and Social Media Presence

Embed Graph

Albireo Pharma News and Updates

Primary Sclerosing Cholangitis - Pipeline Review including key players Acorda Therapeutics Inc, Albireo Pharma Inc, Allergan Plc, Conatus Pharmaceuticals

Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by a progressive course of cholestasis with inflammation and fibrosis of the intrahepatic and extra hepatic bile ducts. Posted via Industry Today. Follow us on Twitter @IndustryToday

Albireo Pharma Blogs

Albireo Announces Research on Cholestatic Liver Diseases to be Presented at Major North American Liver Meetings

Study results to be presented at NASPGHAN demonstrate reductions in bile acids and bilirubin  are highly associated with decreased aggregate need for liver transplant in PFIC patients Findings to be presented by NAPPED Consortium at AASLD The Liver Meeting demonstrate native liver survival rates

Albireo Appoints Simon Harford as Chief Financial Officer and Treasurer

-- Proven CFO with significant financial and business leadership experience -- -- Significant commercialization experience with two global pharma companies -- BOSTON , Oct. 10, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company

Albireo to Present at Cantor Fitzgerald Global Healthcare Conference

Albireo to Present at Cantor Fitzgerald Global Healthcare Conference Content Import Mon, 09/24/2018 - 08:33 Albireo to Present at Cantor Fitzgerald Global Healthcare Conference Sep 24, 2018 This release is a backfill from a News Wire General …

Albireo to Present at Wedbush PacGrow Healthcare Conference

Albireo to Present at Wedbush PacGrow Healthcare Conference Content Import Wed, 08/08/2018 - 08:33 Albireo to Present at Wedbush PacGrow Healthcare Conference Aug 8, 2018 This release is a backfill from a News Wire General BOSTON, Aug…

Albireo to Report Second Quarter 2018 Financial Results, and Host Conference Call and Webcast on August 7, 2018

Albireo to Report Second Quarter 2018 Financial Results, and Host Conference Call and Webcast on August 7, 2018 Content Import Thu, 08/02/2018 - 16:03 Albireo to Report Second Quarter 2018 Financial Results, and Host Conference Call and Webcast on August 7, 2018 Aug 2, 2018 …

Albireo Appoints Patrick Horn MD, PhD as Chief Medical Officer

Albireo Appoints Patrick Horn MD, PhD as Chief Medical Officer Content Import Wed, 07/25/2018 - 08:33 Albireo Appoints Patrick Horn MD, PhD as Chief Medical Officer Jul 25, 2018 This release is a backfill from a News Wire General --- …

Albireo Pharma Frequently Asked Questions

  • When was Albireo Pharma founded?

    Albireo Pharma was founded in 2003.

  • Who are Albireo Pharma key executives?

    Albireo Pharma's key executives are Jason Duncan, Michael Gutch and Pamela Stephenson.

  • How many employees does Albireo Pharma have?

    Albireo Pharma has 55 employees.

  • What is Albireo Pharma revenue?

    Latest Albireo Pharma annual revenue is $8.3 m.

  • What is Albireo Pharma revenue per employee?

    Latest Albireo Pharma revenue per employee is $151.1 k.

  • Who are Albireo Pharma competitors?

    Competitors of Albireo Pharma include McSAF, Yamo Pharmaceuticals and Biodol Therapeutics.

  • Where is Albireo Pharma headquarters?

    Albireo Pharma headquarters is located at 10 Post Office Square #502, Boston.

  • Where are Albireo Pharma offices?

    Albireo Pharma has offices in Boston and Göteborg.

  • How many offices does Albireo Pharma have?

    Albireo Pharma has 2 offices.